Myriad's MRD Opportunity Looks Real-But the Paycheck Still Isn't Showing Up

Myriad's Q2 results highlighted demand, not monetization

Myriad's latest quarter came down to one clear problem: clinicians still appear to want the tests, but the company is not converting that demand into revenue as cleanly as investors hoped.

Revenue fell because reimbursement, not demand, drove the miss

The market reacted quickly. Second-quarter revenue was only $190.7 million, about approximately $15.3 million below Wall Street expectations. Management also cut full-year revenue guidance to $770 million-$790 million and suspended adjusted EBITDA guidance, underscoring that this was a monetization reset rather than a simple guidance wobble.

Demand itself did not break. Myriad reported Cancer Care Continuum test volume growth of 6%, while total volume was down just 1%. What changed was economics: average revenue per test fell 9%. That is why the story remains unresolved. The product has users, but the cash collection is not yet matching the usage.

Reimbursement friction is the gap between test volume and revenue

Myriad's numbers make the split easy to see. In the first quarter, Cancer Care Continuum test volume grew 13% and Precise MRD launched. By the second quarter, the broader Cancer Care Continuum grew 6%, and Precise MRD expanded to additional cancer types. That suggests clinicians are willing to order the tests when they are available.

What weakened was not laboratory demand. It was the money flow. When volume is roughly stable but average revenue per test falls, the pressure is usually upstream at the payer interface: coverage decisions, payment levels, claim flow, and net collections.

Myriad itself pointed to payer friction

Management described elevated payer friction, alongside pricing headwinds and collection challenges. That fits the quarter's mix of decent demand and weak revenue realization.

Precise MRD is a good example of where this friction can show up. Earlier this year, Myriad said the assay would move from research-use-only into a limited clinical launch in March 2026, starting with breast cancer and adding colorectal and renal cancers later that year. Launching into a reimbursement environment that is still catching up can keep a clinically interesting test from translating into predictable revenue.

The fix has to come from payment discipline, not more tests

Myriad said it is activating a multi-quarter program to address reimbursement pressure and is using AI-enabled revenue-cycle tools as part of a broader efficiency push. If those efforts work, the same test volume could produce better revenue over the next few quarters. If they do not, demand will keep looking real while monetization stays uneven.

What would actually prove improvement

The next checkpoint is straightforward: Myriad needs to show that reimbursement and revenue-cycle efforts are improving realization, not just preserving volume.

The near-term signal is stabilization

Investors should watch whether the company can at least stop the slide. A stable or slightly improving quarter after this kind of reset would be meaningful because it would suggest the reimbursement pressure is easing rather than deepening.

Better revenue per test matters more than more volume

The more important signal is economics. If later quarters show improved revenue per test, investors can start to conclude the monetization problem is being fixed from within. More tests with the same low realization would not be enough. The company needs proof that demand is converting into dollars more reliably.